Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Gene Transfer for Severe Combined Immunodeficiency, X-linked (SCID-X1) Using a Self-inactivating (SIN) Gammaretroviral Vector

This study is currently recruiting participants. (see Contacts and Locations)
Verified November 2016 by Boston Children’s Hospital
Sponsor:
Collaborators:
Boston Children’s Hospital
Children's Hospital Medical Center, Cincinnati
University of California, Los Angeles
Information provided by (Responsible Party):
David Williams, Boston Children's Hospital
ClinicalTrials.gov Identifier:
NCT01129544
First received: May 21, 2010
Last updated: November 7, 2016
Last verified: November 2016